Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.

Oksala R, Moilanen A, Riikonen R, Rummakko P, Karjalainen A, Passiniemi M, Wohlfahrt G, Taavitsainen P, Malmström C, Ramela M, Metsänkylä HM, Huhtaniemi R, Kallio PJ, Mustonen MV.

J Steroid Biochem Mol Biol. 2019 Sep;192:105115. doi: 10.1016/j.jsbmb.2018.02.004. Epub 2018 Feb 10. Review.

2.

In vitro methods in the prediction of kinetics of drugs: focus on drug metabolism.

Raunio H, Taavitsainen P, Honkakoski P, Juvonen R, Pelkonen O.

Altern Lab Anim. 2004 Oct;32(4):425-30. Review.

PMID:
15651928
3.

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.

Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O.

Drug Metab Dispos. 2004 Jun;32(6):626-31.

PMID:
15155554
4.

Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.

Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O.

Drug Metab Dispos. 2003 Sep;31(9):1093-102.

PMID:
12920164
5.

Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems.

Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF.

Xenobiotica. 2001 Jun;31(6):321-43.

PMID:
11513246
6.
7.

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.

Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ.

Eur J Clin Pharmacol. 2001 Apr;57(1):37-42.

PMID:
11372588
8.

An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant.

Andersson TB, Sjöberg H, Hoffmann KJ, Boobis AR, Watts P, Edwards RJ, Lake BG, Price RJ, Renwick AB, Gómez-Lechón MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Goldfarb PS, Lewis DF, Corcos L, Guillouzo A, Taavitsainen P, Pelkonen O.

Drug Metab Dispos. 2001 May;29(5):712-20.

PMID:
11302938
10.

Characterization of xenobiotic-metabolizing cytochrome P450 (CYP) forms in ringed and grey seals from the Baltic Sea and reference sites.

Nyman M, Raunio H, Taavitsainen P, Pelkonen O.

Comp Biochem Physiol C Toxicol Pharmacol. 2001 Jan;128(1):99-112.

PMID:
11166678
11.

Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.

Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT.

Drug Metab Dispos. 2000 Aug;28(8):959-65.

PMID:
10901707
12.

In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.

Taavitsainen P, Kiukaanniemi K, Pelkonen O.

Eur J Clin Pharmacol. 2000 May;56(2):135-40.

PMID:
10877007
13.

Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.

Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O.

Pharmacol Toxicol. 2000 May;86(5):215-21.

PMID:
10862503
14.

Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.

Wang JS, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT.

Pharmacol Toxicol. 1999 Nov;85(5):201-5.

PMID:
10608481
15.

Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.

Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT.

Pharmacol Toxicol. 1999 Oct;85(4):157-61.

PMID:
10563513
16.

Inhibition and induction of human cytochrome P450 (CYP) enzymes.

Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H.

Xenobiotica. 1998 Dec;28(12):1203-53. Review. No abstract available.

PMID:
9890159
17.

Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.

Haritos VS, Ching MS, Ghabrial H, Gross AS, Taavitsainen P, Pelkonen O, Battaglia SE, Smallwood RA, Ahokas JT.

Pharmacogenetics. 1998 Oct;8(5):423-32.

PMID:
9825834
18.

CYP2D6 polymorphism is not crucial for the disposition of selegiline.

Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L.

Clin Pharmacol Ther. 1998 Oct;64(4):402-11.

PMID:
9797797
19.

Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes.

Lukkari E, Taavitsainen P, Juhakoski A, Pelkonen O.

Pharmacol Toxicol. 1998 Apr;82(4):161-6.

PMID:
9584328
20.

Site-directed mutagenesis of prostatic acid phosphatase. Catalytically important aspartic acid 258, substrate specificity, and oligomerization.

Porvari KS, Herrala AM, Kurkela RM, Taavitsainen PA, Lindqvist Y, Schneider G, Vihko PT.

J Biol Chem. 1994 Sep 9;269(36):22642-6.

21.

Structural comparison of human and rat prostate-specific acid phosphatase genes and their promoters: identification of putative androgen response elements.

Virkkunen P, Hedberg P, Palvimo JJ, Birr E, Porvari K, Ruokonen M, Taavitsainen P, Jänne OA, Vihko P.

Biochem Biophys Res Commun. 1994 Jul 15;202(1):49-57.

PMID:
8037752

Supplemental Content

Loading ...
Support Center